Exporter

You can select particular sections to be included in the output file.
EN
FR

Liste modèle des médicaments essentiels

effacer Trouvé 253 recommandations pour 85 médicaments et 5 équivalents thérapeutiques
Les médicaments retirés et les demandes rejetées ne sont pas indiqués. Les afficher.
6.2. Antibacterials
  1. Amikacin Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate)
    • Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
    • Parenteral > General injections > unspecified: 50 mg per mL in 2 mL vial (as sulfate); 250 mg per mL in 2 mL vial (as sulfate)
    Indications
    Premier choix
    Neutropenia (high-risk) co-prescrite avec cefotaxime Inflammatory and other diseases of prostate (severe) co-prescrite avec cefotaxime Acute pyelonephritis (severe) co-prescrite avec ceftriaxone Inflammatory and other diseases of prostate (severe) co-prescrite avec ceftriaxone Acute pyelonephritis (severe)
    Second choix
    co-prescrite avec cloxacillin Sepsis without septic shock
    Section
    Antituberculosis medicines
    • Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  2. Amoxicillin Informations générales
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
    • Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection
    • Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)
    • Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)
    • Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate)
    Indications
    Premier choix
    Acute pharyngitis Periapical abscess without sinus Acute sinusitis Acute otitis media Chronic obstructive pulmonary disease with acute exacerbation Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Acute malnutrition in infants, children or adolescents (uncomplicated) [children] Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec gentamicin Sepsis without septic shock
    Second choix
    Bacterial meningitis
  3. Amoxicillin + clavulanic acid Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
    • Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
    • Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)
    • Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)
    • Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)
    Indications
    Premier choix
    Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Infectious cystitis Neutropenia (low-risk) Other specified pneumonia (Hospital-acquired pneumonia) Bacterial cellulitis, erysipelas or lymphangitis Peritonitis (mild-moderate) Acute sinusitis Peritoneal abscess (mild-moderate) Chronic obstructive pulmonary disease with acute exacerbation
    Second choix
    Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Bacterial pneumonia (Community-acquired pneumonia - severe) Bacterial infection of joint Other specified prophylactic measures Osteomyelitis or osteitis Acute otitis media
    Section
    Antituberculosis medicines
    • Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
    • Oral > Solid > dispersible tablet: 250 (as trihydrate) + 62.5 (as potassium salt)
    • Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  4. Ampicillin Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
    Indications
    Premier choix
    Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Acute malnutrition in infants, children or adolescents (complicated) [children] Peritonitis (mild-moderate) Peritonitis (severe) Peritoneal abscess (mild-moderate) Peritoneal abscess (severe) co-prescrite avec gentamicin Sepsis without septic shock
    Second choix
    Bacterial meningitis
  5. Azithromycin Informations générales
    Section
    Watch group antibiotics
    • Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid
    • Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)
    Indications
    Premier choix
    Trachoma Cholera Cholera [children] Paratyphoid fever Chlamydia trachomatis Typhoid fever Yaws co-prescrite avec ceftriaxone Gonococcal infection
    Second choix
    Infectious gastroenteritis or colitis without specification of infectious agent co-prescrite avec cefixime Gonococcal infection
  6. Bedaquiline Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid > tablet: 100 mg tablet; 20 mg tablet
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  7. Benzathine benzylpenicillin Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > IM: 1.2 million IU in vial (≈ 900 mg) powder for injection; 2.4 million IU in vial (≈ 1.8 g) powder for injection
    Indications
    Premier choix
    Congenital syphilis [children] Syphilis
  8. Benzylpenicillin Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
    Indications
    Premier choix
    Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Congenital syphilis [children] Syphilis Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec gentamicin Sepsis without septic shock
    Second choix
    Bacterial meningitis
  9. Cefalexin Informations générales
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
    • Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)
    • Oral > Solid > dispersible tablet: 125 mg; 250 mg
    Indications
    Premier choix
    Bacterial cellulitis, erysipelas or lymphangitis
    Second choix
    Chronic obstructive pulmonary disease with acute exacerbation Acute pharyngitis
  10. Cefazolin Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection
    Indications
    Premier choix
    Other specified prophylactic measures Other specified prophylactic measures
    Second choix
    Bacterial infection of joint Osteomyelitis or osteitis
  11. Cefiderocol Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 1 g in vial (as sulfate tosylate) powder for injection
    Indications
    Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  12. Cefixime Informations générales
    Section
    Watch group antibiotics
    • Oral > Liquid: 100 mg per 5 mL powder for oral liquid
    • Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)
    Indications
    Second choix
    Infectious gastroenteritis or colitis without specification of infectious agent Gonococcal infection
  13. Cefotaxime Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
    Indications
    Premier choix
    Bacterial meningitis Inflammatory and other diseases of prostate (severe) Acute pyelonephritis (severe) Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Bacterial pneumonia (Community-acquired pneumonia - severe) Peritoneal abscess (mild-moderate) Peritoneal abscess (severe) Other specified pneumonia (Hospital-acquired pneumonia) Peritonitis (mild-moderate) Peritonitis (severe)
    Second choix
    Inflammatory and other diseases of prostate (mild to moderate) Acute pyelonephritis (mild to moderate) Sepsis without septic shock Bacterial infection of joint Osteomyelitis or osteitis
  14. Ceftazidime Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection
    Indications
    Premier choix
    Endophthalmitis
    Autres indications
    Pseudomonas aeruginosa resistant to other antibiotic
  15. Ceftazidime + avibactam Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection
    Indications
    Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  16. Ceftolozane + tazobactam Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 1 g + 0.5 g powder for injection
    Indications
    Carbapenem-resistant Pseudomonas aeruginosa
  17. Ceftriaxone Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
    • Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial
    Indications
    Premier choix
    Inflammatory and other diseases of prostate (severe) Bacterial meningitis Acute pyelonephritis (severe) Other specified pneumonia (Hospital-acquired pneumonia) Paratyphoid fever Typhoid fever Peritonitis (mild-moderate) Peritonitis (severe) Peritoneal abscess (mild-moderate) Peritoneal abscess (severe) Gonococcal infection Endophthalmitis Bacterial pneumonia (Community-acquired pneumonia - severe) Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec metronidazole Necrotising fasciitis
    Second choix
    Inflammatory and other diseases of prostate (mild to moderate) Acute pyelonephritis (mild to moderate) Infectious gastroenteritis or colitis without specification of infectious agent Bacterial infection of joint Sepsis without septic shock Osteomyelitis or osteitis
  18. Cefuroxime Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection
    Indications
    Second choix
    Other specified prophylactic measures
  19. Chloramphenicol Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)
    • Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection
    Indications
    Second choix
    Bacterial meningitis
  20. Ciprofloxacin Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 2 mg per mL (as hyclate)
    • Oral > Liquid: 250 mg per 5 mL (anhydrous)
    • Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)
    • Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride)
    Indications
    Premier choix
    Acute pyelonephritis (mild to moderate) Infectious gastroenteritis or colitis without specification of infectious agent Paratyphoid fever Typhoid fever Neutropenia (low-risk) Inflammatory and other diseases of prostate (mild to moderate)
    Second choix
    Cholera Cholera [children] Peritonitis (mild-moderate) Peritoneal abscess (mild-moderate)
  21. Clarithromycin Informations générales
    Section
    Watch group antibiotics
    • Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection
    • Oral > Solid > dosage form: 500 mg; 250 mg
    • Oral > Solid > dosage form: 500 mg
    Indications
    Premier choix
    co-prescrite avec cefotaxime Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescrite avec ceftriaxone Bacterial pneumonia (Community-acquired pneumonia - severe)
    Second choix
    Acute pharyngitis co-prescrite avec amoxicillin + clavulanic acid Bacterial pneumonia (Community-acquired pneumonia - severe)
    Autres indications
    Helicobacter pylori associated gastric ulcer
  22. Clindamycin Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate)
    • Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride)
    • Oral > Solid: 150 mg (as hydrochloride)
    Indications
    Premier choix
    Necrotising fasciitis
    Second choix
    Bacterial infection of joint Osteomyelitis or osteitis
  23. Clofazimine Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid > dosage form: 100 mg; 50 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
    Section
    Antileprosy medicines
    • Oral > Solid > dosage form: 100 mg; 50 mg
    Indications
    Leprosy
  24. Cloxacillin Informations générales
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid
    • Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection
    • Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt)
    Indications
    Premier choix
    Osteomyelitis or osteitis Bacterial infection of joint Bacterial cellulitis, erysipelas or lymphangitis
    Second choix
    co-prescrite avec amikacin Sepsis without septic shock
  25. Colistin (injection) Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium) (equivalent to 34 mg colistin base activity)
    Indications
    Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  26. Cycloserine Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid > dosage form: 250 mg; 125 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  27. Dapsone Informations générales
    Section
    Antileprosy medicines
    • Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet
    Indications
    Leprosy
  28. Delamanid Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 25 mg
    • Oral > Solid > tablet: 50 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  29. Doxycycline Informations générales
    Section
    Access group antibiotics
    • Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium)
    • Parenteral > General injections > unspecified: 100 mg in vial powder for injection
    • Oral > Solid > dispersible tablet: 100 mg (as monohydrate)
    • Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)
    • Oral > Solid > dosage form: 100 mg (as hyclate)
    Indications
    Premier choix
    Cholera Chlamydia trachomatis
    Second choix
    Cholera [children] Chronic obstructive pulmonary disease with acute exacerbation Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)
  30. Erythromycin Informations générales
    Section
    Watch group antibiotics
    Indications
    Second choix
    Therapeutic equivalent to clarithromycin pour Acute pharyngitis
  31. Ethambutol Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 100 mg
    • Oral > Solid > tablet: 100 mg (hydrochloride); 400 mg (hydrochloride)
    Indications
    Tuberculosis
  32. Ethambutol + isoniazid + pyrazinamide + rifampicin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet
    Indications
    Tuberculosis
  33. Ethambutol + isoniazid + rifampicin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 275 mg + 75 mg + 150 mg tablet
    Indications
    Tuberculosis
  34. Ethionamide Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 125 mg
    • Oral > Solid > tablet: 250 mg
    Indications
    Tuberculous meningitis Multi-drug resistant Mycobacterium tuberculosis
  35. Fosfomycin (injection) Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection
    Indications
    Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  36. Gentamicin Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)
    Indications
    Premier choix
    Neonatal meningitis Sepsis without septic shock Sepsis without septic shock Sepsis without septic shock co-prescrite avec amoxicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec ampicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec ampicillin Peritonitis (mild-moderate) co-prescrite avec ampicillin Peritonitis (severe) co-prescrite avec ampicillin Peritoneal abscess (mild-moderate) co-prescrite avec ampicillin Peritoneal abscess (severe) co-prescrite avec ampicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec benzylpenicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec benzylpenicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
    Second choix
    Gonococcal infection Other specified prophylactic measures
  37. Imipenem + cilastatin Informations générales
    Section
    Watch group antibiotics
    Indications
    Second choix
    Therapeutic equivalent to meropenem pour Peritonitis (severe) Therapeutic equivalent to meropenem pour Peritoneal abscess (severe) Therapeutic equivalent to meropenem pour Neutropenia (high-risk)
    Section
    Antituberculosis medicines
    Indications
    Therapeutic equivalent to meropenem pour Multi-drug resistant Mycobacterium tuberculosis
  38. Isoniazid Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 100 mg (scored)
    • Oral > Solid > tablet: 100 mg; 300 mg
    Indications
    Tuberculosis
  39. Isoniazid + pyrazinamide + rifampicin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 50 mg + 150 mg + 75 mg
    Indications
    Tuberculosis
  40. Isoniazid + rifampicin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 50 mg + 75 mg
    • Oral > Solid > tablet: 75 mg + 150 mg; 150 mg + 300 mg
    Indications
    Tuberculosis
  41. Isoniazid + rifapentine Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 300 mg + 300 mg tablet (scored)
    Indications
    Latent tuberculosis
  42. Levofloxacin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 100 mg
    • Oral > Solid > tablet: 250 mg; 500 mg; 750 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  43. Linezolid Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 mg per mL in 300 mL bag
    • Oral > Liquid: 100 mg per 5 mL powder for oral liquid
    • Oral > Solid > dispersible tablet: 150 mg
    • Oral > Solid > tablet: 600 mg
    Indications
    Methicillin resistant Staphylococcus aureus Vancomycin resistant Staphylococcus aureus Vancomycin resistant Enterococcus
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 150 mg (scored)
    • Oral > Solid > tablet: 600 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  44. Meropenem Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
    Indications
    Second choix
    Neonatal meningitis Peritonitis (severe) Peritoneal abscess (severe) Neutropenia (high-risk)
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  45. Meropenem + vaborbactam Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection
    Indications
    Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales Carbapenem resistant Acinetobacter baumannii
  46. Metronidazole Informations générales
    Section
    Access group antibiotics
    • Oral > Liquid: 200 mg per 5 mL (as benzoate)
    • Local > Rectal > Suppository: 500 mg; 1 g
    • Parenteral > General injections > unspecified: 500 mg per 100 mL in vial
    • Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg
    • Oral > Solid > tablet: 500 mg; 200 mg; 250 mg; 400 mg
    Indications
    Premier choix
    Intestinal infections due to Clostridioides difficile Trichomoniasis Necrotising fasciitis co-prescrite avec cefazolin Other specified prophylactic measures co-prescrite avec cefotaxime Peritoneal abscess (mild-moderate) co-prescrite avec cefotaxime Peritoneal abscess (severe) co-prescrite avec cefotaxime Peritonitis (mild-moderate) co-prescrite avec cefotaxime Peritonitis (severe) co-prescrite avec ceftriaxone Peritoneal abscess (mild-moderate) co-prescrite avec ceftriaxone Peritoneal abscess (severe) co-prescrite avec ceftriaxone Peritonitis (mild-moderate) co-prescrite avec ceftriaxone Peritonitis (severe)
    Second choix
    co-prescrite avec ciprofloxacin Peritoneal abscess (mild-moderate) co-prescrite avec ciprofloxacin Peritonitis (mild-moderate)
  47. Moxifloxacin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid > tablet: 400 mg
    • Oral > Solid > dispersible tablet: 100 mg
    Indications
    Tuberculosis Multi-drug resistant Mycobacterium tuberculosis
  48. Nitrofurantoin Informations générales
    Section
    Access group antibiotics
    • Oral > Liquid: 25 mg per 5 mL oral liquid
    • Oral > Solid > dosage form: 100 mg; 50 mg
    Indications
    Premier choix
    Infectious cystitis
  49. P-aminosalicylate sodium Informations générales
    Section
    Antituberculosis medicines
    • Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid) powder for oral solution
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  50. Phenoxymethylpenicillin Informations générales
    Section
    Access group antibiotics
    • Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
    • Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)
    Indications
    Premier choix
    Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Periapical abscess without sinus Acute pharyngitis
  51. Piperacillin + tazobactam Informations générales
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection
    Indications
    Premier choix
    Neutropenia (high-risk) Other specified pneumonia (Hospital-acquired pneumonia) Peritonitis (severe) Peritoneal abscess (severe) co-prescrite avec clindamycin Necrotising fasciitis
  52. Plazomicin Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 500 mg per 10 mL
    Indications
    Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  53. Polymyxin B (injection) Informations générales
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)
    Indications
    Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  54. Pretomanid Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid > tablet: 200 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  55. Procaine benzylpenicillin Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection
    Indications
    Premier choix
    Congenital syphilis [children]
    Second choix
    Syphilis
  56. Protionamide Informations générales
    Section
    Antituberculosis medicines
    Indications
    Therapeutic equivalent to ethionamide pour Multi-drug resistant Mycobacterium tuberculosis
  57. Pyrazinamide Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 150 mg
    • Oral > Solid > tablet: 400 mg; 500 mg
    Indications
    Tuberculosis
  58. Rifabutin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid: 150 mg
    Indications
    Tuberculosis
  59. Rifampicin Informations générales
    Section
    Antituberculosis medicines
    • Oral > Liquid: 20 mg per mL
    • Oral > Solid: 150 mg; 300 mg
    Indications
    Tuberculosis
    Section
    Antileprosy medicines
    • Oral > Liquid: 20 mg per mL
    • Oral > Solid: 150 mg; 300 mg
    Indications
    Leprosy
  60. Rifapentine Informations générales
    Section
    Antituberculosis medicines
    • Oral > Solid > tablet: 150 mg; 300 mg
    • Oral > Solid > dispersible tablet: 150 mg
    Indications
    Tuberculosis Latent tuberculosis
  61. Spectinomycin Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection
    Indications
    Second choix
    Gonococcal infection
  62. Streptomycin (injection) Informations générales
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  63. Sulfamethoxazole + trimethoprim Informations générales
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule
    • Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
    • Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
    • Oral > Solid > dispersible tablet: 100 mg + 20 mg
    Indications
    Premier choix
    Infectious cystitis
    Second choix
    Infectious gastroenteritis or colitis without specification of infectious agent
  64. Tedizolid Informations générales
    Section
    Reserve group antibiotics
    Indications
    Therapeutic equivalent to linezolid pour Methicillin resistant Staphylococcus aureus Therapeutic equivalent to linezolid pour Vancomycin resistant Staphylococcus aureus Therapeutic equivalent to linezolid pour Vancomycin resistant Enterococcus
  65. Terizidone Informations générales
    Section
    Antituberculosis medicines
    Indications
    Therapeutic equivalent to cycloserine pour Multi-drug resistant Mycobacterium tuberculosis
  66. Trimethoprim Informations générales
    Section
    Access group antibiotics
    • Oral > Liquid: 50 mg per mL
    • Oral > Solid: 100 mg; 200 mg
    Indications
    Premier choix
    Infectious cystitis
  67. Vancomycin Informations générales
    Section
    Watch group antibiotics
    • Oral > Solid > capsule: 125 mg (as hydrochloride); 250 mg (as hydrochloride)
    • Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection
    • Parenteral > Locoregional injections > Intravitreal: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection
    Indications
    Premier choix
    Necrotising fasciitis co-prescrite avec ceftazidime Endophthalmitis co-prescrite avec ceftriaxone Endophthalmitis
    Second choix
    Intestinal infections due to Clostridioides difficile Neutropenia (high-risk)